Dr H Ulrich Dorries competitive analysis

Latest publications and patents of Dr H Ulrich Dorries New

Explore the latest publications and patents granted to Dr H Ulrich Dorries, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Dr H Ulrich Dorries against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerASTELLAS PHARMAOct 10, 2024
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSOct 1, 2024
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSAug 1, 2024
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSJul 3, 2024
Novel Tnf Structure For Use In TherapyUCB BIOPHARMAFeb 12, 2024
Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their UsesJANSSEN BIOTECHDec 22, 2022
Fatty Acids And Their Use In Conjugation To BiomoleculesNOVARTISAug 24, 2022
Permanent Epigenetic Gene SilencingFONDAZIONE TELETHONAug 24, 2022
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSJul 5, 2022
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSMay 4, 2022

Latest PTAB cases involving Dr H Ulrich Dorries

Discover the latest PTAB cases involving Dr H Ulrich Dorries, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Dr H Ulrich Dorries with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
DR H ULRICH DORRIES26 - - - Highly Aggressive
GENENTECH - 86 - 65Non-Active
REGENERON PHARMACEUTICALS3893930Balanced
SANOFI BIOTECHNOLOGY - 50 - - Non-Active